(3) Compared with PSA testing, a significant advantage of TMPRSS2:ERG fusion testing is that the ETS gene fusions are specific for neoplastic cells, which is important because prostate cancer tends to be overdiagnosed, partly because of the low specificity of PSA as a screening tool.
TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
Considering the high prevalence of PCa, TMPRSS2:ERG fusion is the most common genetic aberration described to date in human solid tumors .
In a very recent PubMed and Web of Science database search of the peer reviewed literature on urine-based testing for Pca, in an attempt toward the detection of Pca in urine, investigators have identified PCA3 and TMPRSS2:ERG fusion transcripts as promising RNA markers for cancer detection and possibly prognosis .
Urine TMPRSS2:ERG fusion
transcript stratifies prostate cancer risk in men with elevated serum PSA.
They wrote: "The TMPRSS2:ERG fusion
, detected in approximately 50% of prostate cancers, is the most common fusion gene found in human malignancies."
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.
identifies a subgroup of prostatecancers with a favorable prognosis.
Based on these findings, a urinary assay for TMPRSS2:ERG fusion
(T2:ERG) is currently in development using the same platform and technology as the PCA3 assay (18).
We (5) have recently reported a direct analysis of the expression of the TMPRSS2:ERG fusion
gene in surgical samples from a total of 84 patients, 24 of whom had received presurgery androgen ablation therapy.
Seventeen different types of TMPRSS2:ERG fusion
transcripts involving various regions of the TMPRSS2 and ERG genes have been identified (86,99-102); however, 8 of these transcripts are unlikely to result in the translation of functional ERG proteins due to the introduction of premature stop codons.